Sunesis Pharmaceuticals to Host Conference Call on August 7th to Discuss Second Quarter 2018 Financial Results and Recent Hig...
31 July 2018 - 9:00PM
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that
it will host a conference call on Tuesday, August 7th, 2018 at 4:30
p.m. Eastern Time to discuss corporate updates and financial
results for the second quarter ended June 30, 2018.
The call can be accessed by dialing (844) 296-7720 (U.S. and
Canada) or (574) 990-1148 (international) and entering passcode
5198125.
To access the live audio webcast, or the subsequent archived
recording, visit the "Investors and Media - Calendar of Events"
section of the Sunesis website at http://ir.sunesis.com. The
webcast will be recorded and available for replay on the company's
website for one year.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company
developing new therapeutics for the treatment of hematologic and
solid cancers. Sunesis has built an experienced drug development
organization committed to improving the lives of people with
cancer. The Company is focused on advancing its novel
kinase-inhibitor pipeline, with an emphasis on establishing proof
of concept that its oral non-covalent BTK-inhibitor vecabrutinib is
effective in ibrutinib-resistant chronic lymphocytic leukemia.
Vecabrutinib is currently being evaluated in a Phase 1b/2 study in
adults with chronic lymphocytic leukemia and other B-cell
malignancies who have progressed after prior therapies. Beyond the
development of vecabrutinib, the Company has two other kinase
inhibitor programs, including Sunesis’ proprietary preclinical PDK1
inhibitor SNS-510, which is in preclinical development with an IND
submission planned in 2019, and the Takeda-partnered pan-RAF
inhibitor TAK-580, which is in a clinical trial for pediatric
low-grade glioma. PDK1 is a master kinase that activates
other kinases important to cell growth and survival including
members of the AKT, PKC, RSK and SGK families. Sunesis is also
seeking a partner to fund the completion of development for
vosaroxin, a Phase 3 investigational product for relapsed or
refractory AML. For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks
of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries:Maeve
ConneightonArgot Partners212-600-1902
Willie QuinnSunesis Pharmaceuticals
Inc.650-266-3716
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Sunesis Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles